Supplement Documents [IFRS]

Financial results for the first six months of the fiscal year 2014 (FY2014)

ending March 31, 2015.

Astellas Pharma Inc.

- Financial Results of 2Q/FY2014
  - Six months ended September 30, 2014
  - Three months ended September 30, 2014
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

[Six months ended September 30, 2014]

1. Consolidated Results (Full Basis)

billion yen

	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year
Sales	544.1	594.5	50.4	9.3%	1,139.9
Cost of sales	160.7	159.1	-1.6	-1.0%	330.6
Ratio to Sales	29.5%	26.8%			29.0%
Gross profit	383.4	435.4	52.0	13.6%	809.3
SG&A expenses	184.5	201.8	17.3	9.4%	397.0
Ratio to Sales	33.9%	33.9%			34.8%
Advertising and Sales Promotion	51.2	55.0	3.9	7.6%	112.1
Personnel expenses	80.5	85.3	4.8	6.0%	167.8
Other	52.9	61.4	8.5	16.1%	117.0
R&D expenses	90.4	97.0	6.6	7.3%	191.5
Ratio to Sales	16.6%	16.3%			16.8%
Amortisation of intangible assets	17.8	17.9	0.2	0.9%	36.0
Share of profits of associates and joint ventures	1.2	0.5	-0.6	-53.5%	1.5
Other income	0.6	4.9	4.2	674.3%	11.6
Gain on sales of property, plant and equipment	0.0	1.4	1.4	-	5.5
Net foreign exchange gains	-	1.7	1.7	-	-
Other expense	28.7	20.8	-7.8	-27.3%	81.0
Loss on sales and disposal of property, plant and equipment	0.2	0.5	0.3	146.2%	4.1
Impairment losses	17.7	8.3	-9.4	-52.9%	55.8
Restructuring costs	7.5	11.3	3.8	51.1%	10.1
Net foreign exchange losses	2.6	-	-2.6	-	8.0
Operating profit	63.8	103.2	39.4	61.8%	116.8
Ratio to Sales	11.7%	17.4%			10.2%
Finance income	2.2	2.3	0.1	4.9%	6.8
Gain on sales of available-for-sale financial assets	1.3	1.0	-0.2	-18.5%	5.0
Finance expense	0.7	2.8	2.0	275.7%	1.7
Impairment losses for available-for-sale financial assets	0.6	2.6	2.0	318.4%	1.2
Profit before tax	65.2	102.7	37.5	57.5%	122.0
Ratio to Sales	12.0%	17.3%			10.7%
Income tax expense	19.6	32.7	13.1	66.6%	31.1
Profit for the period	45.6	70.0	24.4	53.6%	90.9
Ratio to Sales	8.4%	11.8%			8.0%
Comprehensive income	86.7	87.8	1.1	1.2%	182.1

2. Consolidated Results (Core Basis)

billion yen

	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 (%)
Sales	544.1	594.5	50.4	9.3%	1,139.9	1,192.0	1,210.0	6.1%
Cost of sales	160.7	159.1	-1.6	-1.0%	330.6			
Ratio to Sales	29.5%	26.8%			29.0%			
Gross profit	383.4	435.4	52.0	13.6%	809.3			
SG&A expenses	184.5	201.8	17.3	9.4%	397.0			
Ratio to Sales	33.9%	33.9%			34.8%			
Advertising and Sales Promotion	51.2	55.0	3.9	7.6%	112.1			
Personnel expenses	80.5	85.3	4.8	6.0%	167.8			
Other	52.9	61.4	8.5	16.1%	117.0			
R&D expenses	90.4	97.0	6.6	7.3%	191.5	198.0	200.0	4.5%
Ratio to Sales	16.6%	16.3%			16.8%	16.6%	16.5%	
Amortisation of intangible assets	17.8	17.9	0.2	0.9%	36.0			
Share of profits of associates and joint ventures	1.2	0.5	-0.6	-53.5%	1.5			
Operating profit	91.8	119.2	27.4	29.8%	186.3	208.0	210.0	12.7%
Ratio to Sales	16.9%	20.0%			16.3%	17.4%	17.4%	
Finance income	0.9	1.2	0.3	38.8%	1.6			
Finance expense	0.1	0.2	0.1	43.3%	0.4			
Profit before Tax	92.6	120.2	27.6	29.9%	187.5			
Ratio to Sales	17.0%	20.2%			16.4%			
Income tax expense	29.4	39.2	9.7	33.1%	54.7			
Profit for the period	63.1	81.1	17.9	28.4%	132.8	154.0	154.0	16.0%
Ratio to Sales	11.6%	13.6%			11.6%	12.9%	12.7%	

3. Exchange Rate

yen

	FY13 APR. - SEP.Ave.	FY14 APR. - SEP.Ave.	FY13 End	FY14 2Q End	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year
Yen/USD	99	103	103	109	100	100	104
Yen/EUR	130	139	142	139	134	140	137

∗ Exchange rate fluctuations had positive impact by 18.6 billion yen on sales and positive impact by 8.9 billion yen on Core operating profit in Q2/FY2014

4. Reconciliation of Full Basis to Core Basis

Billion yen

	FY13 APR. - SEP.			FY14 APR. - SEP.		
Account item	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**544.1**	**-**	**544.1**	**594.5**	**-**	**594.5**
Cost of sales	160.7	-	160.7	159.1	-	159.1
Gross profit	**383.4**	**-**	**383.4**	**435.4**	**-**	**435.4**
SG&A expenses	184.5	-	184.5	201.8	-	201.8
R&D expenses	90.4	-	90.4	97.0	-	97.0
Amortisation of intangible assets	17.8	-	17.8	17.9	-	17.9
Share of profits of associates and joint ventures	1.2	-	1.2	0.5	-	0.5
Other income *1	0.6	-0.6	-	4.9	-4.9	-
Other expense *1	28.7	-28.7	-	20.8	-20.8	-
Operating profit	**63.8**	**28.1**	**91.8**	**103.2**	**16.0**	**119.2**
Finance income *2	2.2	-1.3	0.9	2.3	-1.0	1.2
Finance expense *2	0.7	-0.6	0.1	2.8	-2.6	0.2
Profit before tax	**65.2**	**27.4**	**92.6**	**102.7**	**17.6**	**120.2**
Income tax expense	19.6	9.8	29.4	32.7	6.5	39.2
Profit for the period	**45.6**	**17.6**	**63.1**	**70.0**	**11.1**	**81.1**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results.

5. Segment Information by Region

billion yen

		FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 Change (%)
Sales		544.1	594.5	50.4	9.3%	1,139.9	1,192.0	1,210.0	6.1%
	Japan	254.5	237.2	-17.2	-6.8%	530.6	528.4	503.0	-5.2%
	Ratio to Sales	46.8%	39.9%			46.5%	44.3%	41.6%	
	Americas	139.6	168.0	28.4	20.4%	287.0	289.2	328.9	14.6%
	Ratio to Sales	25.7%	28.3%			25.2%	24.3%	27.2%	
	Europe	122.1	156.5	34.4	28.2%	264.3	305.6	307.6	16.4%
	Ratio to Sales	22.4%	26.3%			23.2%	25.6%	25.4%	
	Asia and Oceania	27.9	32.7	4.8	17.1%	58.0	68.7	70.4	21.5%
	Ratio to Sales	5.1%	5.5%			5.1%	5.8%	5.8%	

- Calculated according to locations of sellers.
- Europe: Including Middle East and Africa

6. Per Share Information

	FY13 APR. - SEP.	FY14 APR. - SEP.	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year
The number of shares issued (thousand) *	2,284,823	2,259,823	2,284,823		
Treasury Shares (thousand) *	28,733	51,959	53,681		
The number of shares issued after deducting Treasury Shares (thousand) *	2,256,089	2,207,864	2,231,141		
Earnings per share (Yen) *	20.19	31.61	40.45		
Earnings per share (Yen) core base *	27.99	36.61	59.11	69.02	69.65
Dividend per share (Yen) *	13	14	27	29	30

* The company conducted a 5-for-1 stock split of common stock on April 1, 2014.
These figures are calculated on the assumption that the above stock split was implemented at the beginning of FY2013.

7. Addition to Property, Plant and Equipment
Depreciation/Amortisation

billion yen

		FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	billion yen FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	14.2	10.7	-3.6	-24.9%	25.7	33.0	31.0	20.6%
Depreciation(Tangible)									
	Consolidated	11.3	10.8	-0.4	-3.9%	23.2	23.0	23.0	-0.8%
Amortisation(Intangible) *									
	Consolidated	20.2	20.6	0.4	1.7%	41.1	42.0	43.0	4.6%

* Amortisation(Intangible): Including amortisation of software, etc.

8. Sales of major products

1)Sales of global products

billion yen

	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 (%)
Prograf	89.3	95.2	5.8	6.5%	181.1	181.3	187.5	3.6%
Sales by Astellas	86.6	93.4	6.8	7.8%	175.9	177.6	184.0	4.6%
Japan (Including Graceptor)	25.3	23.7	-1.7	-6.5%	50.4	49.6	48.6	-3.6%
Americas	14.9	16.9	2.1	14.0%	29.6	27.4	32.5	9.6%
Europe	34.6	38.4	3.8	11.0%	70.8	71.4	73.2	3.3%
Advagraf	11.4	14.0	2.5	22.3%	24.0			
Asia and Oceania	11.9	14.4	2.6	21.5%	25.0	29.2	29.8	19.2%
Exports to third parties	2.7	1.8	-0.9	-34.5%	5.2	3.7	3.5	-31.7%
Harnal	29.4	27.4	-2.0	-6.9%	59.5	55.9	56.4	-5.2%
Sales by Astellas	27.1	25.6	-1.6	-5.8%	55.2	52.0	52.1	-5.5%
Japan	10.4	7.8	-2.6	-24.9%	20.2	16.0	14.9	-26.6%
Europe	9.3	9.1	-0.2	-1.8%	19.4	18.7	18.6	-3.8%
Asia and Oceania	7.1	8.4	1.3	18.2%	14.9	16.8	18.1	21.4%
Bulk and Royalties	2.3	1.9	-0.5	-19.7%	4.3	4.0	4.3	-1.6%
Vesicare	63.2	66.6	3.4	5.3%	133.8	120.7	129.9	-3.0%
Japan	14.0	11.8	-2.2	-15.5%	30.7	24.2	26.9	-12.5%
Americas	27.6	30.6	3.0	10.8%	58.1	48.2	55.7	-4.1%
Europe	19.4	21.4	2.0	10.1%	40.8	42.9	41.7	2.2%
Asia and Oceania	2.0	2.4	0.4	21.7%	3.8	4.8	5.1	32.9%
Betanis/Myrbetriq/BETMIGA	10.6	22.3	11.7	110.1%	28.2	56.4	52.4	85.7%
Japan	4.8	6.1	1.3	26.7%	11.6	20.9	14.7	26.8%
Americas	5.4	12.2	6.8	125.8%	14.5	25.9	26.9	85.5%
Europe	0.4	4.0	3.6	829.7%	2.1	9.3	10.3	400.1%
Funguard/MYCAMINE	17.6	18.5	0.9	5.0%	36.1	36.8	38.1	5.5%
Japan	6.0	5.7	-0.3	-5.1%	12.3	11.4	11.9	-3.3%
Americas	6.0	5.7	-0.3	-4.9%	11.7	10.9	11.3	-3.9%
Europe	4.1	5.1	1.0	24.8%	8.6	10.1	10.7	24.2%
Asia and Oceania	1.5	2.0	0.5	31.0%	3.4	4.4	4.1	22.7%
Protopic	12.0	12.1	0.0	0.4%	25.0	19.7	19.7	-21.1%
Americas	5.7	6.5	0.8	13.8%	11.7	8.4	9.0	-22.5%
Europe	3.1	3.9	0.8	24.2%	7.1	7.4	7.5	6.8%
Asia and Oceania	1.4	1.6	0.3	20.0%	2.6	3.6	3.1	21.5%
XTANDI	20.5	54.6	34.1	166.1%	54.6			
US	18.9	33.5	14.6	77.6%	44.3	56.0	71.8	62.2%
ex-US	1.7	21.1	19.5	-	10.3			
Japan	-	5.6	5.6	-	-			
Americas (ex-US)	0.1	0.9	0.8	607.5%	0.8			
Europe	1.5	14.5	12.9	849.6%	9.5	26.6	31.5	233.2%
Asia and Oceania	-	0.1	0.1	-	0.0			
Eligard	8.9	9.5	0.6	6.8%	18.3			
Europe	8.9	9.4	0.6	6.6%	18.3	20.9	19.6	7.1%
Asia and Oceania	-	0.0	0.0	-	0.0			

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 Change (%)
Prograf （Including Graceptor）	25.3	23.7	-1.7	-6.5%	50.4	49.6	48.6	-3.6%
Harnal	10.4	7.8	-2.6	-24.9%	20.2	16.0	14.9	-26.6%
Vesicare	14.0	11.8	-2.2	-15.5%	30.7	24.2	26.9	-12.5%
Betanis	4.8	6.1	1.3	26.7%	11.6	20.9	14.7	26.8%
Funguard	6.0	5.7	-0.3	-5.1%	12.3	11.4	11.9	-3.3%
XTANDI	-	5.6	5.6	-	-			
<Local products in Japan>								
Lipitor [Family]	32.1	24.5	-7.6	-23.6%	62.4	52.6	47.1	-24.5%
Caduet	5.3	5.2	-0.1	-1.5%	10.7			
Micardis [Family]	47.3	47.1	-0.2	-0.5%	97.6	97.5	99.3	1.7%
Micombi	5.8	5.4	-0.4	-6.9%	11.8			
Micamlo	10.1	11.4	1.4	13.5%	21.4			
Gaster	13.3	9.5	-3.8	-28.7%	25.7	19.5	17.9	-30.5%
Myslee	14.4	9.8	-4.5	-31.5%	28.2	20.2	19.7	-30.2%
Seroquel	10.4	6.6	-3.7	-36.1%	19.6	12.6	12.6	-35.6%
Vaccines	10.6	12.6	2.0	19.1%	35.0	35.7	37.1	6.2%
Cefzon	3.2	2.6	-0.7	-20.5%	6.4	5.3	5.3	-16.9%
Celecox	20.6	19.6	-1.0	-4.9%	44.3	45.9	42.6	-3.8%
Geninax	4.9	4.3	-0.6	-12.5%	11.7	12.4	12.0	1.7%
Bonoteo	6.5	6.1	-0.4	-6.5%	14.1	14.7	13.5	-4.4%
Symbicort	15.2	14.5	-0.7	-4.5%	35.6	36.3	35.3	-1.0%
Argamate	3.1	2.9	-0.1	-3.6%	6.1	6.4	5.9	-3.4%
Kiklin	0.6	0.7	0.1	17.0%	1.4	2.1	1.8	21.9%
Gonax	1.0	1.6	0.6	55.3%	2.5	4.8	3.9	51.6%
Cimzia	1.3	2.4	1.1	84.3%	3.2	12.3	6.0	85.1%
Suglat	-	2.6	2.6	-	-			
Total Rx Sales In Japanese market	247.0	229.5	-17.5	-7.1%	515.6	508.3	487.0	-5.5%

- Sales of products in Japan are shown in a gross sales basis.

billion yen

3)Sales of products in Americas and Europe	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 Change (%)
Scan* (Americas)	33.0	32.2	-0.8	-2.5%	61.8	53.3	61.1	-1.3%
Lexiscan	30.5	32.1	1.6	5.2%	58.6			
AmBisome (Americas)	4.1	4.2	0.1	1.8%	8.1	8.0	8.3	3.0%
Tarceva	22.9	24.7	1.8	8.0%	44.7			
(US)	15.1	17.2	2.2	14.4%	28.9			
(ex-US)	7.8	7.5	-0.3	-4.2%	15.9			
Qutenza (Europe)	0.6	0.9	0.2	33.3%	1.4			
DIFICLIR (Europe)	0.6	1.0	0.4	74.8%	1.3			

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 (%)
Net Sales	1,412	1,631	218	15.5%	2,863	2,892	3,162	10.4%
Prograf	150	164	14	9.3%	296	274	312	5.6%
Scan*	334	313	-22	-6.5%	617	533	587	-4.9%
Lexiscan	308	311	3	1.0%	585			
AmBisome	41	40	-1	-2.4%	80	80	80	-0.7%
Protopic	58	63	5	9.1%	116	84	87	-25.3%
VESIcare	279	296	17	6.3%	580	482	536	-7.6%
Myrbetriq	55	118	64	116.6%	145	259	259	78.8%
MYCAMINE	60	55	-5	-8.8%	117	109	109	-7.4%
Tarceva	232	240	8	3.6%	446			
US	153	167	15	9.7%	288			
ex-US	79	73	-6	-8.1%	158			
XTANDI	192	334	142	73.9%	450			
US	191	325	134	70.3%	441	560	690	56.3%
Americas (ex-US)	1	9	8	578.7%	8			

* Adenoscan + Lexiscan

Unit:M€

Europe	FY13 APR. - SEP.	FY14 APR. - SEP.	Change	Change (%)	FY13 Full Year	Initial Forecasts FY14 Full Year	Revised Forecasts FY14 Full Year	Change from FY13 FY14 (%)
Net Sales	939	1,127	187	20.0%	1,967	2,183	2,246	14.2%
Harnal (Omnic)	89	79	-10	-11.4%	176	162	167	-5.2%
Sales by Astellas	72	66	-6	-8.1%	144	133	136	-5.6%
Capsule	33	33	0	0.1%	69	66	69	-0.3%
OCAS	39	33	-6	-15.0%	75	67	68	-10.5%
Bulk and Royalties	18	13	-4	-24.8%	32	29	31	-3.4%
Prograf	286	289	3	1.0%	565	536	560	-1.0%
Sales by Astellas	266	276	10	3.9%	527	510	534	1.3%
Advagraf	88	100	13	14.4%	179			
Exports to third parties	20	13	-7	-36.5%	38	26	26	-32.5%
Vesicare	149	154	5	3.1%	303	307	304	0.3%
BETMIGA	3	29	26	770.0%	15	66	75	390.6%
Protopic	24	28	4	16.3%	52	53	55	4.8%
MYCAMINE	31	37	5	16.8%	64	72	78	21.9%
Eligard	68	68	-0	-0.2%	136	149	143	5.1%
Qutenza	5	6	1	25.9%	11			
DIFICLIR	4	7	3	65.0%	9			
XTANDI	12	104	92	788.6%	70	190	230	226.9%

- Europe: Including Middle East and Africa

9.Consolidated statements of financial position

Billion yen

			31-Mar-14	30-Sep-14	
			Amount	Amount	Change
Assets			**1,653.1**	**1,715.3**	**62.2**
	Non-current assets		**739.8**	**749.0**	**9.2**
		Property, plant and equipment	191.5	192.8	1.4
		Goodwill	116.8	124.2	7.4
		Other intangible assets	280.1	278.2	-1.9
		Investments in associates and joint ventures	1.8	1.8	-0.0
		Deferred tax assets	45.5	50.9	5.3
		Other financial assets	95.0	89.9	-5.1
		Other non-current assets	9.2	11.2	2.1
	Current assets		**913.3**	**966.4**	**53.1**
		Inventories	135.2	154.6	19.4
		Trade and other receivables	332.6	333.6	0.9
		Income tax receivable	2.7	1.8	-0.9
		Other financial assets	35.4	42.2	6.8
		Other current assets	12.1	12.3	0.2
		Cash and cash equivalents	391.4	421.3	30.0
		Assets held for sale	3.9	0.6	-3.3

Billion yen

	31-Mar-14	30-Sep-14	
	Amount	Amount	Change
Equity and Liabilities	**1,653.1**	**1,715.3**	**62.2**
Equity	**1,268.5**	**1,295.2**	**26.7**
Equity attributable to owners of the parent	**1,268.5**	**1,295.2**	**26.7**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	-
Treasury shares	-54.5	-59.1	-4.6
Retained earnings	864.8	880.1	15.2
Other components of equity	178.4	194.4	16.0
Liabilities	**384.6**	**420.2**	**35.5**
Non-current liabilities	**43.9**	**45.1**	**1.1**
Trade and other payables	0.1	0.1	0.0
Deferred tax liabilities	0.0	0.1	0.1
Retirement benefit liabilities	27.2	25.1	-2.1
Provisions	4.3	4.0	-0.2
Other financial liabilities	0.7	0.7	-0.1
Other non-current liabilities	11.7	15.1	3.4
Current liabilities	**340.7**	**375.1**	**34.4**
Trade and other payables	187.0	212.8	25.8
Income tax payable	13.2	14.0	0.8
Provisions	66.4	70.9	4.5
Other financial liabilities	1.1	7.4	6.3
Other current liabilities	73.0	70.1	-2.9

10. Employee

Number of employees

	FY13 2Q End	FY14 2Q End	FY13 FY End
Total	17,455	17,536	17,649
Japan	8,186	7,698	8,082
Americas	2,855	2,939	2,883
Europe	4,355	4,681	4,580
Asia and Oceania	2,059	2,218	2,104
Total Medical Representatives	6,280	6,540	6,340

- Europe: Including Middle East and Africa

11. Shareholders

	FY13 2Q End	FY14 2Q End
Banks	30.2%	30.5%
Securities	4.2%	3.6%
Other companies	3.7%	3.4%
Foreign companies	52.2%	52.7%
Individuals and others	8.6%	7.5%
Treasury Stock	1.3%	2.3%

[Three months ended September 30, 2014]

1. Consolidated Results (Full Basis)

bilion yen

	FY14			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%
Cost of sales	76.0	-6.4%	83.1	4.5%
Ratio to Sales	25.7%		27.8%	
Gross profit	219.2	16.4%	216.2	10.8%
SG&A expenses	96.9	6.3%	104.9	12.3%
Ratio to Sales	32.8%		35.0%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%
Personnel expenses	42.4	3.0%	42.9	9.2%
Other	26.3	3.2%	35.1	28.1%
R&D expenses	47.6	8.0%	49.4	6.6%
Ratio to Sales	16.1%		16.5%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%
Other income	2.7	-	2.9	470.8%
Gain on sales of property, plant and equipment	0.0	27.9%	1.4	-
Net foreign exchange gains	2.5	-	-	-
Other expense	18.1	-0.6%	3.5	-66.8%
Loss on sales and disposal of property, plant and equipment	0.2	20.2%	0.4	406.3%
Impairment losses	8.1	-30.3%	0.3	-95.8%
Restructuring costs	9.3	99.5%	2.0	-28.8%
Net foreign exchange losses	-	-	0.7	-19.2%
Operating profit	50.6	91.5%	52.6	40.9%
Ratio to Sales	17.1%		17.6%	
Finance income	1.8	183.5%	0.4	-70.7%
Gain on sales of available-for-sale financial assets	0.9	-	0.2	-85.1%
Finance expense	2.1	213.3%	0.7	898.8%
Impairment losses for available-for-sale financial assets	2.0	220.1%	0.6	-
Profit before tax	50.3	90.6%	52.4	35.0%
Ratio to Sales	17.0%		17.5%	
Income tax expense	14.4	120.0%	18.3	39.8%
Profit for the period	35.9	80.9%	34.1	32.6%
Ratio to Sales	12.1%		11.4%	
Comprehensive income	22.5	-59.8%	65.3	112.8%

2. Consolidated Results (Core Basis)

bilion yen

	FY14			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%
Cost of sales	76.0	-6.4%	83.1	4.5%
Ratio to Sales	25.7%		27.8%	
Gross profit	219.2	16.4%	216.2	10.8%
SG&A expenses	96.9	6.3%	104.9	12.3%
Ratio to Sales	32.8%		35.0%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%
Personnel expenses	42.4	3.0%	42.9	9.2%
Other	26.3	3.2%	35.1	28.1%
R&D expenses	47.6	8.0%	49.4	6.6%
Ratio to Sales	16.1%		16.5%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%
Operating profit	66.0	48.2%	53.2	12.4%
Ratio to Sales	22.4%		17.8%	
Finance income	1.0	55.6%	0.3	-1.2%
Finance expense	0.1	112.4%	0.1	-8.3%
Profit before Tax	66.8	48.3%	53.4	12.4%
Ratio to Sales	22.6%		17.8%	
Income tax expense	20.4	53.3%	18.8	16.4%
Profit for the period	46.4	46.2%	34.6	10.4%
Ratio to Sales	15.7%		11.6%	

3. Segment Information by Region

bilion yen

		FY14			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales		295.2	9.5%	299.3	9.0%
	Japan	112.8	-9.5%	124.4	-4.1%
	Ratio to Sales	38.2%		41.6%	
	Americas	83.8	21.9%	84.2	18.9%
	Ratio to Sales	28.4%		28.1%	
	Europe	82.4	32.9%	74.1	23.4%
	Ratio to Sales	27.9%		24.7%	
	Asia and Oceania	16.1	15.1%	16.7	19.0%
	Ratio to Sales	5.4%		5.6%	

- Calculated according to locations of sellers.
- Europe: Including Middle East and Africa

4. Addition to Property, Plant and Equipment
Depreciation/Amortisation

bilion yen

		FY14			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment					
	Consolidated	3.4	-31.6%	7.3	-21.4%
Depreciation(Tangible)					
	Consolidated	5.3	-7.1%	5.6	-0.8%
Amortisation(Intangible) *					
	Consolidated	10.2	1.8%	10.4	1.7%

* Amortisation(Intangible): Including amortisation of software, etc.

5. Sales of major products

1)Sales of global products

bilion yen

	FY14			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Prograf	47.0	6.6%	48.1	6.5%
Sales by Astellas	46.2	7.6%	47.3	8.0%
Japan (Including Graceptor)	11.4	-8.9%	12.2	-4.2%
Americas	8.8	22.1%	8.1	6.3%
Europe	18.6	9.2%	19.7	12.8%
Advagraf	6.6	18.8%	7.3	25.6%
Asia and Oceania	7.3	20.5%	7.2	22.5%
Exports to third parties	0.9	-29.2%	0.9	-39.1%
Harnal	13.7	-10.2%	13.7	-3.3%
Sales by Astellas	12.5	-10.2%	13.0	-1.1%
Japan	3.9	-24.3%	3.9	-25.5%
Europe	4.5	-10.5%	4.6	8.7%
Asia and Oceania	4.0	11.5%	4.4	25.0%
Bulk and Royalties	1.2	-9.6%	0.6	-33.8%
Vesicare	33.0	4.4%	33.6	6.3%
Japan	5.3	-25.0%	6.5	-5.9%
Americas	15.5	15.6%	15.0	6.2%
Europe	11.0	8.3%	10.4	12.1%
Asia and Oceania	1.2	22.6%	1.2	20.8%
Betanis/Myrbetriq/BETMIGA	10.7	128.2%	11.6	95.9%
Japan	2.7	12.2%	3.4	41.2%
Americas	6.2	187.3%	6.0	85.2%
Europe	1.8	-	2.2	679.9%
Funguard/MYCAMINE	8.9	6.7%	9.6	3.5%
Japan	2.5	-10.2%	3.2	-0.7%
Americas	2.8	0.7%	2.8	-9.8%
Europe	2.7	34.0%	2.4	16.0%
Asia and Oceania	0.9	21.1%	1.1	39.5%
Protopic	6.0	-1.2%	6.0	2.0%
Americas	3.1	8.6%	3.4	19.0%
Europe	2.1	29.5%	1.7	18.4%
Asia and Oceania	0.8	14.1%	0.9	25.7%
XTANDI	23.4	174.6%	31.3	160.1%
US	14.7	80.4%	18.8	75.4%
ex-US	8.7	-	12.4	866.4%
Japan	1.5	-	4.1	-
Americas (ex-US)	0.4	-	0.5	322.9%
Europe	6.7	-	7.8	567.4%
Asia and Oceania	0.0	-	0.1	-
Eligard	5.1	9.5%	4.4	3.8%
Europe	5.1	9.4%	4.4	3.6%
Asia and Oceania	0.0	-	0.0	-

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle East and Africa

2)Sales of products in Japan

bilion yen

	FY14			
	APR.-JUN.	Change	JUL.-SEP.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)
Prograf （Including Graceptor）	11.4	-8.9%	12.2	-4.2%
Harnal	3.9	-24.3%	3.9	-25.5%
Vesicare	5.3	-25.0%	6.5	-5.9%
Betanis	2.7	12.2%	3.4	41.2%
Funguard	2.5	-10.2%	3.2	-0.7%
XTANDI	1.5	-	4.1	-
<Local products in Japan>				
Lipitor [Family]	12.1	-22.8%	12.4	-24.3%
Caduet	2.6	-0.6%	2.6	-2.4%
Micardis [Family]	23.3	-1.6%	23.8	0.6%
Micombi	2.7	-6.8%	2.7	-7.0%
Micamlo	5.7	6.1%	5.8	21.8%
Gaster	4.8	-27.5%	4.7	-29.9%
Myslee	4.8	-30.8%	5.0	-32.2%
Seroquel	3.4	-34.7%	3.2	-37.5%
Vaccines	5.3	10.1%	7.3	26.6%
Cefzon	1.2	-18.9%	1.3	-21.9%
Celecox	8.4	-15.7%	11.3	5.2%
Geninax	2.3	-20.9%	2.0	-0.3%
Bonoteo	2.6	-14.9%	3.4	1.1%
Symbicort	6.2	-17.5%	8.3	8.3%
Argamate	1.5	-3.8%	1.5	-3.5%
Kiklin	0.3	14.7%	0.4	18.9%
Gonax	0.8	63.9%	0.9	48.4%
Cimzia	1.1	95.4%	1.3	75.4%
Suglat	2.5	-	0.1	-
Total Rx Sales In Japanese market	109.0	-9.9%	120.5	-4.3%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

bilion yen

		FY14			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Scan*	(Americas)	16.6	-3.0%	15.6	-2.0%
Lexiscan		16.5	4.6%	15.6	6.0%
AmBisome	(Americas)	1.9	-1.9%	2.3	5.0%
Tarceva		13.6	11.6%	11.2	4.0%
	(US)	9.6	18.8%	7.6	9.2%
	(ex-US)	3.9	-2.7%	3.6	-5.7%
Qutenza	(Europe)	0.4	35.3%	0.4	31.2%
DIFICLIR	(Europe)	0.5	92.9%	0.5	60.3%

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY14 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Net Sales	821	17.8%	810	13.2%
Prograf	86	18.1%	78	1.1%
Scan*	163	-6.2%	150	-6.7%
Lexiscan	161	1.1%	150	0.8%
AmBisome	19	-5.2%	22	0.1%
Protopic	31	5.0%	32	13.3%
VESIcare	152	11.8%	145	1.0%
Myrbetriq	60	177.7%	58	76.2%
MYCAMINE	28	-2.7%	27	-14.2%
Tarceva	133	7.9%	107	-1.2%
US	94	14.8%	73	3.7%
ex-US	38	-6.0%	34	-10.3%
XTANDI	148	79.2%	187	70.0%
US	144	74.4%	181	67.2%
Americas (ex-US)	4	-	5	303.1%

* Adenoscan + Lexiscan

Unit:M€

Europe	FY14 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Net Sales	589	22.3%	538	17.5%
Harnal (Omnic)	41	-17.4%	38	-3.8%
Sales by Astellas	32	-17.6%	33	3.5%
Capsule	16	-10.6%	17	13.1%
OCAS	16	-23.4%	17	-4.6%
Bulk and Royalties	9	-16.8%	5	-36.4%
Prograf	139	-1.8%	149	3.9%
Sales by Astellas	133	0.5%	143	7.2%
Advagraf	47	9.4%	53	19.3%
Exports to third parties	6	-34.2%	6	-38.7%
Vesicare	78	-0.3%	76	6.8%
BETMIGA	13	-	16	638.2%
Protopic	15	19.2%	13	12.9%
MYCAMINE	19	23.4%	18	10.4%
Eligard	36	0.7%	32	-1.3%
Qutenza	3	24.5%	3	27.4%
DIFICLIR	3	77.6%	4	54.7%
XTANDI	48	-	56	530.6%

- Europe: Including Middle East and Africa

R&D Pipeline (October 2014)

1. Global Development

(1) Approval/Labeling Revision

#Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin#	Remarks
MDV3100 enzalutamide	XTANDI (Sep. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer*1	US	Oral	Medivation	
	XTANDI (Labeling revision in Oct. 2014)		Castration-resistant prostate cancer*2	Japan			

*1 Indication expanded for metastatic castration-resistant prostate cancer to include patients who have not yet received chemotherapy.
*2 Following description was removed in the precautions for indications; the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

(2) Filed

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated	Europe Filed (Apr. 2014)	Oral	Medivation	New indication
		Non-Metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication
erlotinib	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US	Oral	In-house (co-development with Roche/ Genentech)	Pediatric ependymoma is not a new indication, rather a supplement which was submitted to the FDA to fulfill Pediatric Written Request.

(3) Phase-Ⅲ / Phase-Ⅱ (1/2)

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	Europe/US/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Cubist	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III (US/Europe Phase-II*)	Oral	In-house	

*A license agreement was executed with Janssen Biotech, Inc. for the development and commercialization worldwide except for Japan.
Phase-IIb studies were completed by Astellas.

(3) Phase-lll / Phase-ll (2/2)

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP4901 (AKP-002)	PDE9 inhibitor	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Japan Phase-II	Oral	ASKA	
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			

2. Local Development: Japan

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Disease modifying anti-rheumatic drugs (DMARD)-naive rheumatoid arthritis	Japan Filed (Jun. 2014)	Injection	UCB	New indication
nateglinide	Fast acting insulin secretion enhancer	Type 2 diabetes Combination with DPP-4 inhibitor	Japan Filed (Jul. 2014)	Oral	Ajinomoto Pharmaceuticals	New indication
YM060 ramosetron	5-HT3 receptor antagonist	Irritable bowel syndrome with diarrhea in female patients	Japan Filed (Jul. 2014)	Oral	In-house	New indication

(2) Phase-lll / Phase-ll (1/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication
FK949E quetiapine	Serotonin/dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Phase-III	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral		New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hyperlipidemia	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 102 rilotumumab	Anti-HGF monoclonal antibody	Gastric cancer	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	

(2) Phase-lll / Phase-ll (2/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP7991	Calcium-sensing receptor activator	Secondary hyperparathyroidism	Japan Phase-II	Oral	In-house	

3. Local Development: Europe

(1) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral diabetic neuropathy	Europe Phase-III	Patch	NeurogesX	New indication

4. Local Development: US

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
isavuconazole	Azole antifungal	Invasive aspergillosis and invasive mucormycosis	US Filed (Jul. 2014)	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US Phase-III			New indication

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Origin
AGS-16M8F/ AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP9226	Neuropathic pain	Oral	In-house
ASP3662	Alzheimer's disease	Oral	In-house
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP2215	Cancer	Oral	In-house
ASP3325	Hyperphosphatemia	Oral	In-house
CK-2127107	Skeletal muscle disease (non-neuromuscular indications)	Oral	Cytokinetics
ASP5878	Cancer	Oral	In-house
AMG 337	Gastric cancer	Oral	Amgen (co-development with Amgen Astellas)
ASP8273	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
ASP7657	Diabetic nephropathy	Oral	In-house
ASP3700	Osteoarthritis	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP5633	Stress urinary incontinence	Oral	In-house

6. Project Discontinued

Code No. Generic Name	Target Disease	Area / Phase	Reason
ASP3652	Bladder pain syndrome / Interstitial cystitis	Europe Phase-II Japan Phase-I	Development of ASP3652 was discontinued because the Phase-II study did not demonstrate the expected efficacy.

<Changes from the Previous Announcement on August 1, 2014> (Changed underlined items)

Approved / Labeling Revision

-Enzalutamide: The indication expanded in US and the labeling revised in Japan.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	XTANDI (Sep. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer*1	US	Oral	Medivation	
	XTANDI (Labeling revision in Oct. 2014)		Castration-resistant prostate cancer*2	Japan			

*1 Indication expanded for metastatic castration-resistant prostate cancer to include patients who have not yet received chemotherapy.

*2 Following description was removed in the precautions for indications; the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

Filed, Phase-III / Phase-II

-Enzalutamide: Phase-III study being prepared for prostate cancer in patients with non-metastatic biochemical recurrence in US, Europe and Asia.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated	Europe Filed (Apr. 2014)	Oral	Medivation	New indication
		Non-Metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication

-Erlotinib: Submitted pediatric data to the FDA to fulfill Pediatric Written Request.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
erlotinib	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US	Oral	In-house (co-development with Roche/ Genentech)	Pediatric ependymoma is not a new indication, rather a supplement which was submitted to the FDA to fulfill Pediatric Written Request.

-ASP8232: Entered into Phase-II for diabetic nephropathy and diabetic macular edema.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			

-Linaclotide: Entered into Phase-III for irritable bowel syndrome with constipation and Phase-II for chronic constipation.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			

Project Discontinued

-ASP3652: Discontinued the development for bladder pain syndrome / interstitial cystitis (Phase-II in Europe and Phase-I in Japan).